Valneva shares up 17.5% over the quarter and among the leaders of the SBF 120

A leading stock that remains below its long-term averages

Valneva shares gain 2.88% to €2.61 intraday, while the SBF 120 rises 0.52%. The stock thus ranks among the leading pack of the index.

Over the week, the gain is 1.76%, and the stock is trading 17.45% above its level of three months ago, but it is still down 34.51% over one year.

The price is above the MA20 (gap of +4.20%), while remaining below the MA50 (gap of -2.43%) and the MA200 (gap of -10.17%).

Support at €2.33 and resistance at €2.77 frame the session. The stock also benefits from a more supportive market backdrop following Wall Street's rise on Wednesday (S&P 500 up 1.58%).

Valneva is listed in Paris and on the Nasdaq in the form of ADSs (one ADS for two ordinary shares), but the bulk of trading volume takes place in Paris.

A busy calendar: decision on the Lyme disease vaccine expected

When it published its first-half 2026 results on August 13, Valneva confirmed its outlook for the year, despite the impact of the geopolitical context on travel. Among its opportunities, it cited regulatory decisions expected on its Lyme disease vaccine candidate within the following twelve months. It also mentioned an expected improvement in gross margins in the second half.

The stock had fallen 8% over one month in early November before recovering in recent days. Sanofi, another vaccine sector stock, is trading almost flat this Thursday (-0.17%), after a 19.96% gain over one month. The €2.77 level remains the threshold to clear in order to extend the recovery.